Phase 3
Completed N=244
A Study to Compare the Pharmacokinetics of Mepolizumab as a Liquid Drug in a Safety Syringe or an Autoinjector Versus Lyophilised Drug
Source: ClinicalTrials.gov NCT03014674 ↗Enrolled (actual)
244
Serious AEs
0.0%
Results posted
Aug 2018
Primary outcomePrimary: Maximum Observed Plasma Concentration (Cmax) of Mepolizumab — 11.57; 11.98; 12.07 micrograms per milliliter (µg/mL)
◆ Published Evidence
Established
21citations · ~4 / year
The Pharmacokinetics and Relative Bioavailability of Mepolizumab 100 mg Liquid Formulation Administered Subcutaneously to Healthy Participants: A Randomized Trial.
Summary
Mepolizumab (SB-240563) is a humanized monoclonal antibody (Immunoglobulin G1, kappa, mAb) that blocks human interleukin-5 (hIL-5) from binding to the interleukin (IL)-5 receptor complex expressed on the eosinophil cell surface and thus inhibits signaling. This study will compare the pharmacokinetics and safety of mepolizumab administered as a liquid drug product in two different devices with the reconstituted lyophilized drug product in healthy subjects. Subjects will receive a single administration of 100 milligram (mg) mepolizumab as a single injection. The randomization will be stratified by body weight ( =80 kg) and the site of injection will be randomized 1:1:1 to the upper arm, abdomen or thigh. Approximately 243 healthy subjects will be randomized so that at least 9 subjects are randomized to each mepolizumab treatment within each weight strata and 3 subjects within each mepolizumab treatment, weight strata and injection site. Each subject will participate in the study for up to approximately 16 weeks (up to 85 days after drug administration), and will have a screening visit, a single dose treatment period, and a follow-up visit.
Linked Publications
-
The Pharmacokinetics and Relative Bioavailability of Mepolizumab 100 mg Liquid Formulation Administered Subcutaneously to Healthy Participants: A Randomized Trial.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Maximum Observed Plasma Concentration (Cmax) of Mepolizumab |
11.57; 11.98; 12.07 | — |
| PRIMARY Area Under the Plasma Concentration Time Curve (AUC) From Time Zero to the Time of Last Quantifiable Concentration (AUC[0-t]), AUC From Time Zero Extrapolated to Infinite Time (AUC[0-inf]) of Mepolizumab |
403.84; 434.49; 415.15; 450.83; 478.06; 454.11 | — |
| SECONDARY Time to Cmax (Tmax) and Last Time Point Where the Concentration is Above the Limit of Quantification (Tlast) of Mepolizumab |
7.04; 7.05; 7.06; 83.97; 83.98; 83.99 | — |
| SECONDARY Apparent Clearance (CL/F) of Mepolizumab |
0.009242; 0.008716; 0.009175 | — |
| SECONDARY Apparent Volume of Distribution (Vd/F) of Mepolizumab |
7.02; 6.74; 6.94 | — |
| SECONDARY Terminal Phase Elimination Rate Constant (Lambda z) of Mepolizumab |
0.0013157; 0.0012930; 0.0013228 | — |
| SECONDARY Terminal Phase Half-life (t½) of Mepolizumab |
21.95; 22.34; 21.83 | — |
| SECONDARY Percentage of AUC(0-inf) Obtained by Extrapolation (% AUCex) of Mepolizumab |
7.67; 7.64; 7.20 | — |
| SECONDARY Number of Participants With On-treatment Non-serious Adverse Events (AEs) and Serious AEs (SAEs) |
11; 13; 14; 0; 0; 0 | — |
| SECONDARY Number of Participants With On-treatment Systemic Reactions and Injection Site Reactions |
0; 0; 0; 1; 1; 2 | — |
| SECONDARY Number of Participants With Hematology Parameters Shifts From Baseline Relative to Normal Range |
NA; NA; NA; 85; 79; 80 | — |
| SECONDARY Number of Participants With Clinical Chemistry Parameters Shifts From Baseline Relative to Normal Range |
1; 0; 0; 83; 79; 80 | — |
| SECONDARY Change From Baseline in Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) |
1.9; 3.1; 3.0; 0.2; 1.7; 0.8 | — |
| SECONDARY Change From Baseline in Pulse Rate |
5.3; 5.6; 6.1; 4.5; 5.0; 5.0 | — |
| SECONDARY Change From Baseline in Temperature |
0.08; 0.08; 0.01; 0.09; 0.07; -0.02 | — |
| SECONDARY Change From Baseline in Respiratory Rate |
0.0; 0.3; 0.5; -0.2; 0.3; 0.1 | — |
| SECONDARY Number of Participants With Change From Baseline in Electrocardiogram (ECG) Findings |
15; 16; 19; 1; 0; 1 | — |
| SECONDARY Number of Participants With Positive Anti-mepolizumab Binding Antibodies |
1; 1; 0; 2; 4; 3 | — |
| SECONDARY Number of Participants With Positive Neutralizing Antibodies |
0; 0; 0 | — |
Eligibility Criteria
Inclusion Criteria
- 18 years of age and over at the time of signing the informed consent.
- Healthy as determined by the investigator or medically qualified designee based on a medical evaluation including medical history, physical examination, vital signs, laboratory tests, and cardiac monitoring. A subject with a clinical abnormality or laboratory parameter(s) which is/are not specifically listed in the inclusion or exclusion criteria, outside the reference range for the population being studied may be included only if the investigator agrees and documents that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures or ability to interpret study results.
- Body weight >=50 kg and body mass index (BMI) within the range 19.0-30 kg/square meter(m^2) (inclusive)
- Male or Female: A female subject is eligible to participate if she is not pregnant (as confirmed by a negative human chorionic gonadotrophin (hCG) test), not lactating, and at least one of the following conditions applies: Non-reproductive potential defined as: pre-menopausal females with documented tubal ligation; documented hysteroscopic tubal occlusion procedure with follow-up; confirmation of bilateral tubal occlusion; hysterectomy; documented bilateral oophorectomy; post- menopausal females. Subject is of reproductive potential and agrees to follow one of the options listed in the Modified List of Highly Effective Methods for Avoiding Pregnancy in Females of Reproductive Potential (FRP) from 30 days prior to the first dose of study medication and until 16 weeks after the administration of the single dose of study medication.
- Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the consent form and in the protocol. The subject must be able to understand and communicate in the native language of the site, e.g. German in German sites.
Exclusion Criteria
- Alanine transaminase >1.5x upper limit of normal (ULN)
- Bilirubin >1.5xULN (isolated bilirubin >1.5x ULN is acceptable if bilirubin is fractionated and direct bilirubin 450 milliseconds (msec)
- Any clinically relevant abnormality identified at the screening medical assessment (physical examination/medical history), clinical laboratory tests, or 12-lead electrocardiogram.
- Use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements (including St John's Wort) within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half lives (whichever is longer) before the first dose of study medication and until study completion, unless in the opinion of the investigator and GlaxoSmithKline Medical Monitor the medication will not interfere with the study procedures or compromise subject safety.
- History of regular alcohol consumption within 6 months of the study defined as: an average weekly intake of >14 units for females and >21 units for males. One unit is equivalent to 8 grams of alcohol: a half-pint (~240 milliliter [mL]) of beer, 1 glass (125 mL) of wine or 1 (25 mL) measure of spirits.
- Urinary nicotine levels indicative of smoking or history or regular use of tobacco- or nicotine-containing products within 6 months prior to screening. Limit of >500 nanogram/mL.
- Involved in any activities likely to result in any significant decrease or increase in body weight during the study period (e.g. 'crash' dieting, bodybuilding).
- History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the investigator or Medical Monitor, contraindicates their participation.
- Presence of hepatitis B surface antigen (HBsAg), positive hepatitis C antibody test result at screening or within 3 months prior to first dose of study treatment.
- A positive test for human immunodeficiency virus antibody.
- Subjects with known, pre-existing helminthes infestation within 6 months prior to Day 1.
Data sourced from ClinicalTrials.gov (NCT03014674) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.